balance equationreview2019-12-31
Difference 25642000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$76.20M
Fiscal year ended 2025-12-31Operating income
-$22.36M
Fiscal year ended 2025-12-31Free cash flow
-$75.81M
Fiscal year ended 2025-12-31CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.20M and net income of -$17.37M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CytomX Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M | $68.43M | $26.90M | $59.50M | $71.62M | $15.04M |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$22.36M | $25.00M | -$6.48M | -$101.34M | -$116.04M | -$80.54M | -$141.48M | -$77.87M | -$46.26M | -$59.59M |
| Net income | -$17.37M | $31.87M | -$569.00K | -$99.32M | -$115.87M | -$64.82M | -$132.82M | -$84.60M | -$43.10M | -$58.90M |
| Research & development | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M | $112.94M | $131.62M | $103.87M | $92.28M | $54.76M |
| Weighted-average diluted shares | shares 137.94M | shares 84.75M | shares 73.81M | shares 65.74M | shares 64.15M | shares 46.15M | shares 45.34M | Unavailable | Unavailable | Unavailable |
| Pretax income | -$17.13M | $32.09M | $3.32M | -$99.32M | -$115.87M | -$78.73M | -$133.25M | -$70.30M | -$43.61M | -$58.92M |
| Income tax expense | $238.00K | $224.00K | $3.89M | $0 | $0 | -$13.91M | -$427.00K | $14.30M | -$513.00K | -$19.00K |
| Diluted EPS | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $29.84M | $29.73M | $30.02M | $42.85M | $39.16M | $36.03M | $36.76M | $33.51M | $25.60M | $19.87M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M | $191.86M | $188.42M | $247.58M | $177.55M | $104.64M |
| Total assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M | $341.28M | $457.11M | $397.64M | $199.13M |
| Current assets | $143.92M | $107.30M | $182.94M | $237.10M | $310.30M | $324.01M | $303.34M | $445.48M | $388.60M | $188.15M |
| Total liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $339.87M | $366.44M | $290.17M | $326.22M | $327.75M | $120.65M |
| Current liabilities | $46.62M | $85.77M | $155.91M | $152.61M | $77.87M | $68.11M | $85.59M | $97.91M | $61.15M | $35.77M |
| Total equity incl. NCI | $99.01M | -$456.00K | -$47.45M | -$85.75M | -$459.00K | -$7.77M | $25.47M | $135.83M | $69.90M | $78.48M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $2.01M | $3.10M | $3.43M | $35.99M | $790.00K | $798.00K | $13.00K | $97.00K | $10.14M | $2.16M |
| Goodwill | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $1.30M | $1.09M | $1.46M | $2.81M | $2.82M | $3.00M | $4.16M | $5.13M | $4.20M | $6.60M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.59M | -$86.23M | -$56.04M | -$110.79M | -$119.03M | $5.26M | -$140.48M | -$75.52M | $170.37M | -$2.03M |
| Capital expenditures | $220.00K | $310.00K | $840.00K | $1.74M | $1.61M | $2.31M | $3.50M | $3.79M | $1.56M | $2.18M |
| Investing cash flow | -$59.74M | $99.70M | -$150.67M | $98.26M | $22.49M | -$18.72M | $79.70M | $5.93M | -$121.27M | $45.86M |
| Financing cash flow | $110.45M | $7.52M | $30.23M | $648.00K | $110.21M | $16.89M | $1.63M | $139.62M | $23.80M | $996.00K |
| Net change in cash | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $72.90M | $44.82M |
| Stock-based compensation | $6.30M | $7.67M | $8.56M | $13.12M | $13.17M | $14.79M | $19.10M | $16.88M | $11.29M | $10.10M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $1.88M | $1.64M | $1.73M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$75.81M | -$86.54M | -$56.88M | -$112.53M | -$120.64M | $2.95M | -$143.98M | -$79.31M | $168.81M | -$4.21M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | -29.3% | 18.1% | -6.4% | -190.6% | -311.0% | -117.7% | -525.9% | -130.9% | -64.6% | -396.1% |
| FCF margin | -99.5% | -62.7% | -56.2% | -211.7% | -323.3% | 4.3% | -535.2% | -133.3% | 235.7% | -28.0% |
| SBC / revenue | 8.3% | 5.6% | 8.5% | 24.7% | 35.3% | 21.6% | 71.0% | 28.4% | 15.8% | 67.1% |
| Current ratio | 3.09x | 1.25x | 1.17x | 1.55x | 3.98x | 4.76x | 3.54x | 4.55x | 6.36x | 5.26x |
| Revenue YoY growth | -44.8% | 36.4% | 90.4% | 42.5% | -45.5% | 154.4% | -54.8% | -16.9% | 376.1% | Unavailable |
| Net margin | -22.8% | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% | -493.7% | -142.2% | -60.2% | -391.5% |
| R&D / revenue | 90.2% | 60.4% | 76.7% | 210.0% | 306.1% | 165.0% | 489.3% | 174.6% | 128.8% | 364.0% |
| CapEx / revenue | 0.3% | 0.2% | 0.8% | 3.3% | 4.3% | 3.4% | 13.0% | 6.4% | 2.2% | 14.5% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | 0.7% | 117.1% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CTMX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2018-12-31
Difference 4945000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.